Relay Therapeutics, INC Form 4 insider transactions

Relay Therapeutics' Chief Financial Officer, Thomas Catinazzo, sold 21,664 shares of common stock to cover tax obligations related to RSU vesting.

Relay Therapeutics' President of R&D, Donald A. Bergstrom, sold 30,897 shares of common stock at $7.29 per share to cover tax obligations from RSU vesting.

Relay Therapeutics' Chief Corporate Development Officer, Peter Rahmer, sold 17,083 shares of common stock across two transactions to cover income tax withholding obligations related to RSU vesting.

Relay Therapeutics' Chief Financial Officer, Thomas Catinazzo, sold shares of common stock on two separate dates in July 2025 to satisfy tax withholding obligations related to restricted stock unit vesting.

Relay Therapeutics' President of R&D, Donald A. Bergstrom, sold common stock totaling 30,770 shares across two transactions to cover tax withholding obligations related to RSU vesting.

Relay Therapeutics' Chief Legal Officer, Brian Adams, sold shares of common stock to cover income tax withholding obligations related to the vesting of restricted stock units.

Relay Therapeutics' President and CEO, Sanjiv Patel, sold 61,379 shares of common stock to satisfy tax withholding obligations related to RSU vesting.

Relay Therapeutics, Inc. Chief Corporate Development Officer Peter Rahmer acquired 5,000 shares of common stock at $2.94 per share through the company's Employee Stock Purchase Plan.

Relay Therapeutics, Inc. President and CEO, Sanjiv Patel, acquired 5,000 shares of common stock through the company's Employee Stock Purchase Plan at a discounted price.

Relay Therapeutics, Inc. Director Claire Mazumdar was granted 421,241 stock options with an exercise price of $3.36, vesting over 36 months.

Relay Therapeutics, Inc. director Linda A. Hill was granted 136,681 stock options with an exercise price of $3.36, vesting over the next year or by the next annual meeting.

Relay Therapeutics, Inc. Director Alexis Borisy has acquired 136,681 stock options with an exercise price of $3.36, as reported in a recent SEC Form 4 filing.

Relay Therapeutics, Inc. Director Douglas S. Ingram was granted 136,681 stock options with an exercise price of $3.36, vesting on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders.

Relay Therapeutics, Inc. Director Kathiresan Sekar was granted 136,681 stock options with an exercise price of $3.36, vesting on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders.

Relay Therapeutics, Inc. Director Mark Murcko was granted 136,681 stock options with an exercise price of $3.36, vesting over the next year, as disclosed in a recent SEC Form 4 filing.

Relay Therapeutics, Inc. director Jami Rubin was granted 136,681 stock options with an exercise price of $3.36, vesting on the earlier of June 6, 2026, or the next annual meeting of stockholders.

Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, sold shares to cover income tax withholding obligations related to vesting restricted stock units.

Thomas Catinazzo, CFO of Relay Therapeutics, sold shares of common stock to cover income tax withholding obligations related to vesting restricted stock units.

Donald A. Bergstrom, President of R&D at Relay Therapeutics, sold shares to cover income tax withholding obligations related to vesting restricted stock units.

Brian Adams, Chief Legal Officer of Relay Therapeutics, sold shares to cover income tax withholding obligations related to vesting restricted stock units.

Sanjiv Patel, President and CEO of Relay Therapeutics, sold shares of common stock to cover income tax withholding obligations upon the vesting of restricted stock units.

Donald A. Bergstrom, President of R&D at Relay Therapeutics, sold 986 shares of common stock to cover income tax withholding obligations upon the vesting of restricted stock units.

Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, sold 247 shares of common stock on March 27, 2025, to cover income tax withholding obligations upon the vesting of restricted stock units.

Thomas Catinazzo, CFO of Relay Therapeutics, sold shares to cover income tax withholding obligations upon the vesting of restricted stock units.

Brian Adams, Chief Legal Officer of Relay Therapeutics, sold 298 shares of common stock on March 27, 2025, to cover income tax withholding obligations upon the vesting of restricted stock units.

Sanjiv Patel, CEO of Relay Therapeutics, reports the sale and acquisition of common stock related to the vesting of restricted stock units (RSUs) to cover income tax withholding obligations.

A Relay Therapeutics executive, Peter Rahmer, sold shares to cover tax obligations following the vesting of restricted stock units (RSUs), while also receiving additional RSUs.

Relay Therapeutics' Chief Financial Officer, Thomas Catinazzo, sold shares to cover tax obligations from vesting restricted stock units and executed pre-planned trades, while also receiving new restricted stock units.

Relay Therapeutics' President of R&D, Donald A. Bergstrom, sold shares to cover tax obligations following the vesting of restricted stock units (RSUs).

Brian Adams, Chief Legal Officer of Relay Therapeutics, sold shares to cover tax obligations following the vesting of restricted stock units and was also granted additional RSUs.